Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer.
Khuloud BajboujRizwan QaisarMohammed A AlshuraZeinab IbrahimMohamad B AlebajiAmenah W Al AniHanadi M JanajrahMariah M BilalagaAbdelrahman I OmaraRebal S Abou AssalehMaha Saber AyadAdel B ElmoselhiPublished in: International journal of molecular sciences (2022)
Our result is the first to report the synergistic anti-angiogenic potential of combination therapy of Lenvatinib and Regorafenib. Therefore, it shows their therapeutic potential in breast cancer, including the aggressive types. Further studies are warranted to confirm and explore this therapeutic approach.